Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?
Current Oncology · 2023
DOI: 10.3390/curroncol30010098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Mehrsa Jalalizadeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas 13083-970, SP, Brazil. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, B7-H1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Since the 2018 Nobel prize in medicine was granted to the discovery of immune escape by cancer cells, billions of dollars have been spent on a new form of cancer immunotherapy called immune checkpoint inhibition (ICI). In this treatment modality, monoclonal antibodies (mAbs) are used to block cell-surface glycoproteins responsible for cancer immune escape. However, only a subset of patients benefit from this treatment. In this commentary, we focus on the polymorphism in the target molecules of these mAbs, namely PD-1, PD-L1 and CTLA4; we explain that using a single mAb from one clone is unlikely to succeed in treating all humans because humans have a genotype and phenotype polymorphism in these molecules. Monoclonal antibodies are highly specific and are capable of recognizing only one epitope (“monospecific”), which makes them ideal for use in laboratory animals because these animals are generationally inbred and genetically identical (isogenic). In humans, however, the encoding genes for PD-1, PD-L1 and CTLA4 have variations (alleles), and the final protein products have phenotype polymorphism. This means that small differences exist in these proteins among individual humans, rendering one mAb too specific to cover all patients. Our suggestion for the next step in advancing this oncotherapy is to focus on methods to tailor the mAb treatment individually for each patient or replace a single clone of mAb with less specific alternatives, e.g., a “cocktail of mAbs”, oligoclonal antibodies or recombinant polyclonal antibodies. Fortunately, there are ongoing clinical trials on oligoclonal antibodies at the moment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas 13083-970, SP, Brazil.
- Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas 13034-685, SP, Brazil.
ORCID-Profile: Mehrsa Jalalizadeh, Leonardo Oliveira Reis
Zitieren
APA
Jalalizadeh, M., Yadollahvandmiandoab, R., & Reis, L. O. (2023). Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?. Current Oncology. https://doi.org/10.3390/curroncol30010098
Vancouver
Jalalizadeh M, Yadollahvandmiandoab R, Reis LO. Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?. Current Oncology. 2023. doi:10.3390/curroncol30010098
BibTeX
@article{Jalalizadeh2023,
author = {Jalalizadeh, Mehrsa and Yadollahvandmiandoab, Reza and Reis, Leonardo Oliveira},
title = {Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30010098}
}
EUVIMED